GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients

Investigations of the 21-gene Oncotype DX assay in neoadjuvant settings for breast cancer patients are currently underdeveloped. It is still unclear whether any individual gene of the 16 cancer-related genes can be used to predict response to taxane-based neoadjuvant chemotherapy. Here, we performed...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Translational cancer research 2019-04, Vol.8 (2), p.655-663
Hauptverfasser:	Zhang, Guochun, Qian, Xueke, Ren, Chongyang, Wen, Lingzhu, Lyu, Haitong, Liao, Ning
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!